David Erritzoe
Clinical Associate Professor in Psychopharmacology
Data updated
Research Footprint
David Erritzoe appears in 83 tracked papers (2011–2026), most studied alongside Psilocybin, MDMA and Placebo, across Depressive Disorders, Neuroimaging & Brain Measures and Anxiety Disorders.
Most-cited paper: Trial of Psilocybin versus Escitalopram for Depression (1334 citations).
Frequent co-authors: Robin Carhart-Harris, David Nutt and Leor Roseman.
Background & Research
David Erritzoe is a Danish-born psychiatrist and researcher based at Imperial College London. He serves as the Clinical Associate Professor in Psychopharmacology and the Head of the Centre for Psychedelic Research. He also directs the CIPPRes Clinic, focusing on the clinical application of psychedelics in psychiatry. His research utilizes neuroimaging (PET, MRI, EEG) to explore the neurobiology of mental illness and addiction.
Key Impact
Head of the Centre for Psychedelic Research at Imperial College London and director of the CIPPRes Clinic.
Collaboration Network
89 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations David Erritzoe is associated with.